Kyverna Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
KYTX$5.08-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $96,621 | $34,647 |
| Available-for-sale marketable securities | 189,358 | 22,896 |
| Prepaid expenses and other current assets | 4,622 | 3,121 |
| Total current assets | 290,601 | 60,664 |
| Restricted cash | 552 | 565 |
| Property and equipment, net | 3,347 | 2,326 |
| Operating lease right-of-use assets | 6,468 | 6,494 |
| Finance lease right-of-use assets | 841 | 1,790 |
| Other non-current assets | 2,836 | 3,356 |
| Total assets | $304,645 | $75,195 |
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities | ||
| Accounts payable | $4,624 | $4,358 |
| Accrued compensation | 4,883 | 2,812 |
| Accrued license expense – related party | 6,250 | 6,250 |
| Other accrued expenses and current liabilities | 14,059 | 3,519 |
| Operating lease liabilities, short-term portion | 3,161 | 1,964 |
| Finance lease liabilities, short-term portion | 779 | 956 |
| Total current liabilities | 33,756 | 19,859 |
| Operating lease liabilities, net of short-term portion | 4,160 | 5,238 |
| Finance lease liabilities, net of short-term portion | 142 | 921 |
| Total liabilities | 38,058 | 26,018 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible preferred stock, no par value; no shares authorized, issued and outstanding as of December 31, 2024; $0.00001 par value, 114,556,997 shares authorized as of December 31, 2023; 114,556,997 shares issued and outstanding as of December 31, 2023; liquidation preference of $181,273 as of December 31, 2023 | — | 180,574 |
| Stockholders’ equity (deficit) | ||
| Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding as of December 31, 2024; no shares authorized, issued, and outstanding as of December 31, 2023 | — | — |
| Common stock, $0.00001 par value; 490,000,000 and 140,492,016 shares authorized as of December 31, 2024 and 2023, respectively; 43,214,918 and 1,250,103 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — |
| Additional paid-in capital | 530,002 | 4,642 |
| Accumulated other comprehensive income | 105 | 4 |
| Accumulated deficit | (263,520) | (136,043) |
| Total stockholders’ equity (deficit) | 266,587 | (131,397) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $304,645 | $75,195 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.